Exactech Welcomes Orthopaedic Sales Veteran Stuart Kleopfer as Senior VP of Global Sales

October 02, 2018

GAINESVILLE, Fla.–(BUSINESS WIRE)–Exactech, a developer and producer of innovative implants, instrumentation and computer-assisted technologies for joint replacement surgery announced today the appointment of Stuart Kleopfer as Senior Vice President of Global Sales, effective Oct. 1, 2018.

Kleopfer will provide leadership for Exactech’s global sales functions with responsibility for the United States sales organization and the company’s current international team. Kleopfer is a veteran of the orthopaedics industry with 30 years experience in sales and marketing. He had a distinguished career at Biomet that included serving as president, U.S. Commercialization, and then with ZimmerBiomet where he served as president, Americas, until 2017.

“I am excited to be back in orthopaedics and look forward to re-engaging with surgeons and sales representatives,” Kleopfer said. “Exactech has a great product offering and with what we have in the research and development pipeline, I am confident we will be able to strengthen our global sales channel, generate top line revenue and grow market share.”

According to Exactech CEO David Petty, “Stuart is a great addition to Exactech and an excellent fit for our surgeon-focused culture. It’s an exciting time of growth for the company and we are eager to leverage Stuart’s expertise,” he said.

Exactech Co-Executive Chairman Jeff Binder also commented, “We are excited to add Stuart, with his proven track record of success, to the Exactech team and I am looking forward to working with him again.”

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments, and biologic materials, as well as computer assistance and other Augmented OrthopaedicTM technologies to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products throughout the United States and in more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at www.exac.com.


Exactech Inc.
Media Contact
Priscilla Bennett, 352-377-1140
Vice President, Corporate & Marketing Communication

Lambda Technologies Extends the Life of Orthopedic Implants

Lambda Technologies has developed a surface treatment for modular orthopedic implants that eliminates the chance of failure from fretting fatigue. Low plasticity burnishing (LPB®) applies a deep, beneficial surface layer of designed residual compression to mitigate fretting fatigue in titanium implants. By putting the edge of contact region in high residual compression much deeper than the shallow shear cracks formed by fretting, the cracks cannot propagate and the chance of fracture from fretting is eliminated.

Millions of people have regained their mobility because of hip or knee implant technology. Day- to-day activities of the implant recipient, particularly those who are active, can lead to repeated metal-to-metal sliding contact in the joint, leaving the implant vulnerable to fretting induced fatigue cracks and, potentially, failure in the edge-of-contact region. If failure does occur, revision surgeries are required, significantly affecting the quality of life of patients. Fatigue testing of the modular hip and knee prosthesis systems by original manufacturers showed that LPB treatment improves the baseline fatigue strength by nominally 40%, and completely eliminated the occurrence of fretting induced failure.

The FDA has approved Lambda’s LPB process for extending the life of modular prostheses. During the twelve-plus years that orthopedic surgeons have been using LPB treated hip implants, and approximately three years of LPB treated knee implants, no LPB processed implant has failed from fretting fatigue. Dr. N. Jayaraman, Director of Materials Research for Lambda Technologies noted that, “The cost savings and improvement in the quality of life for patients is immeasurable. And as an added bonus, the ease of implementation of LPB into existing production environments in CNC mills or lathes has made it very cost-effective for the manufacturers.“

Lambda Technologies is an innovative company incorporating a premier materials research laboratory with a world-class engineering and production enterprise dedicated to the development and optimization of surface treatments to improve component performance. For additional information on Lambda Technologies or the LPB process, contact Julie Prevéy at (513) 561-0883 or visit http://www.lambdatechs.com.

Medacta International Appoints Francesco Siccardi its Next Chief Executive Officer

October 01, 2018

CASTEL SAN PIETRO, Switzerland–(BUSINESS WIRE)–Medacta® International, the privately held, family-owned global leader in the design of innovative joint replacement and spinal surgery products, today announced that Francesco Siccardi, a noted biomedical engineer and current Executive Vice President of Medacta International, will become the company’s next chief executive officer on November 1, 2018. After nearly twenty years at the helm of the company, Medacta’s founder, Dr. Alberto Siccardi, will transition from his current CEO role and remain President of the company’s Board of Directors.

“It has been tremendously gratifying to see Medacta’s focus on medical education and sustainability resonate with surgeons and healthcare organizations around the world and to know that, together, we have changed orthopedics for tens of thousands of patients and their families,” said Dr. Alberto Siccardi, who founded Medacta following his own experience as a hip replacement surgery patient. “Medacta’s continued growth and prosperity make this an opportune time to transition to the next generation of the company’s leadership. With a deep understanding of both the technical and commercial sides of our business, Francesco is the right person to lead Medacta into the next phase of its evolution.”

Francesco Siccardi has served as Executive Vice President of Medacta International since 2010. A biomechanical engineer by training, he has been instrumental in the conception, development, and manufacture of many of Medacta’s leading products, including the AMIS® (Anterior Minimally Invasive Surgery) product line for total hip replacement, GMK® Sphere Total Knee System, MyKnee® Patient-Matched Technology, Efficiency Single Use Instruments, and the recently launched Medacta Shoulder System. Additionally, he was the driving force behind the creation of the Medacta Spine and Sports Medicine divisions. Francesco Siccardi joined Medacta in 2002 after studying Biomedical Engineering at the Politecnico of Milan.

“Medacta was borne out of my father’s experience as a patient, when he realized that orthopedic care should and could be better for both patient and surgeon alike. The company’s success is testament to that initial vision, and to the hard work behind it,” said Francesco Siccardi. “Over the past twenty years, Medacta has opened hundreds of surgeon learning centers, expanded into several new surgical disciplines, supported research efforts around the world, and changed the face of orthopedics in the process. The future is bright, and I am ecstatic to lead our talented Medacta team toward it.”

With Francesco Siccardi, the next generation of the Siccardi family will take over the operational responsibility of Medacta International. Francesco will be supported by the other two children of Dr. Alberto Siccardi: Alessandro Siccardi, a Board Member and head of the company’s supply chain, and Maria Luisa Siccardi, who also serves as a member of the company’s Board. Together with Medacta’s talented team of 930 employees, the organization strives to realize its mission to improve the patient experience emphasizing medical education, healthcare sustainability and responsible innovation.

About Medacta International

Medacta® International is a world leading company, developer and supplier, specializing in joint replacement, spine surgery, and sports medicine solutions. Medacta’s revolutionary approach and responsible innovation, focusing on Minimally Invasive Solutions and Personalized Medicine, have resulted in standard of care breakthroughs in hip replacement with the AMIS® system and total knee replacement with MyKnee® patient matched technology. Medacta has grown dramatically by taking a different approach and placing value on all aspects of the care experience from design to training to sustainability. Medacta is headquartered in Castel San Pietro, Switzerland, operates in over 30 countries around the globe, and employs more than 930 people. To learn more about Medacta International, please visit www.medacta.com or follow @Medacta on Twitter and LinkedIn.


For Medacta International
Jill Bongiorni, 516-729-2250

Ethicon’s Novel Skin Closure System Leads To Higher Patient And Surgeon Satisfaction After Total Knee Replacement

SOMERVILLE, N.J.Sept. 24, 2018 /PRNewswire/ — Total knee replacement patients and their surgeons were more satisfied with the cosmetic results and less worried about after care and possible infections when the DERMABOND PRINEO Skin Closure System was used to close the knee’s surgical incision rather than traditional skin staples, according to a new quantitative research study conducted by Ethicon,* part of the Johnson & Johnson Medical Devices Companies,** the manufacturer of the novel skin closure device that combines a topical skin adhesive with a self-adhering patch.1

As a replacement for sutures or staples, the DERMABOND PRINEO System provides minimally invasive closure — no holes in the skin; no sutures or staples to remove, and no dressing changes, which may potentially reduce follow-up visits and support good cosmetic results for patients.2 The DERMABOND PRINEO System has been used to close the surgical incisions of more than 1 million patients.

The double-blinded quantitative study (90% CI) of 88 total knee replacement patients and 83 orthopaedic surgeons, found more patients had overall greater satisfaction with the proven DERMABOND PRINEO System (88.2% vs. 81.8%) and were happier with the appearance of their skin incision (80% vs. 71%). Fewer patients were worried about post-operative care (55% vs. 63%) or concerned about complications (56% vs. 60%) when the DERMABOND PRINEO System was used.

Orthopaedic surgeons were more satisfied with the DERMABOND PRINEO System too, but by even wider margins than their patients. Overall surgeon satisfaction was 83.7 percent compared to 56.1 percent for skin staples. Surgeons felt the System led to greater overall patient satisfaction (84% vs. 45%), better cosmetic results (88% vs. 40%) and better overall healing of the knee incision (82% vs. 52%). Surgeons were also less worried about surgical site infections (77% vs. 52%).

“I like DERMABOND PRINEO because I think it creates a water tight skin closure of the arthrotomy, which is important for addressing some of the risk factors for surgical site infections and is also nice for the patient,” said Dr. Ryan Nunley,***Associate Professor of Orthopaedic Surgery at Washington UniversitySt. Louis MO, and orthopaedic surgeon at Barnes Jewish Hospital. “With PRINEO, the patient may start showering soon after the procedure and feel like a normal person again, and mentally I think this helps them achieve a faster recovery period.  We don’t see the train track appearance of staples and don’t need to have home nurses come to the house to remove staples or do wound management, so there is the convenience factor as well, and this is also a cost savings by eliminating the home nursing visits or additional office visits as we enter into the world of bundled payments for total joint,” said Dr. Nunley.

The new research adds to a growing body of evidence showing the value of the DERMABOND PRINEO System in orthopaedic surgery. Recently, two economic analyses demonstrated that its use may be associated with improved patient outcomes and lower healthcare costs for hospitals.3,4 Both studies were presented at the International Society for Pharmacoeconomics and Outcomes Research’s 22nd Annual International Meeting in 2017.

Building on a legacy of 20 years in topical skin adhesives, Ethicon offers a comprehensive portfolio of skin closure systems for a wide variety of incision lengths and closure strength needs, including DERMABOND PRINEO Skin Closure system (42cm) – a new configuration for longer incisions to address growing customer needs in hip, knee and spine surgery. The DERMABOND family of products are the only skin closure devices backed by an extensive body of evidence, including 5,718 patients across 51 Randomized Controlled Trials (RCTs).****

For complete indications, contraindications, warnings, precautions, and adverse reactions associated with the DERMABOND PRINEO System, reference the full package insert.

About the Johnson & Johnson Medical Devices Companies

The Johnson & Johnson Medical Devices Companies** have been working to make surgery better for more than a century. With substantial breadth and depth in surgical and orthopaedic technologies and interventional solutions, we aspire to improve and enhance medical care for people worldwide. Together, we are working to shape the future of health through differentiated products and services.

About Ethicon

From creating the first sutures, to revolutionizing surgery with minimally invasive procedures, Ethicon, part of the Johnson & Johnson Medical Devices Companies, has made significant contributions to surgery for more than 60 years. Our continuing dedication to Shape the Future of Surgery is built on our commitment to help address the world’s most pressing health care issues, and improve and save more lives. Through Ethicon’s surgical technologies and solutions including sutures, staplers, energy devices, trocars and hemostats and our commitment to treat serious medical conditions like obesity and cancer worldwide, we deliver innovation to make a life-changing impact. Learn more at www.ethicon.com, and follow us on Twitter @Ethicon and LinkedIn.

*Ethicon represents the products and services of Ethicon, Inc., Ethicon Endo-Surgery, LLC and certain of their affiliates. Ethicon, LLC is the legal manufacturer of DERMABOND® PRINEO® and STRATAFIX™ Knotless Tissue Control Devices. All other trademarks are the property of their respective owners.
**The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, interventional and specialty solutions businesses within Johnson & Johnson’s Medical Devices segment. 
***Dr. Ryan Nunley is a paid consultant for Ethicon.
****Based on published literature in PubMed and SCOPUS, using only RCTs that evaluated the use of the product in a manner consistent with intended indication.

©2018 Ethicon, Inc.

1 Double-blinded quantitative research study comparing surgeon experience with DERMABOND PRINEO System (22 cm) and skin staples in total knee arthroplasty. N=83 Orthopaedic surgeons. 90% CI. Fielded June/July 2017.
2 Ethicon Inc. DERMABOND PRINEO Skin Closure System (22cm) Instructions for Use. LAB100114233v2. 5/15
3Johnston S, Sutton N. Comparison of Economic and Clinical Outcomes between the Dermabond® Prineo® Skin Closure System and Skin Staples in Patients Undergoing Knee Replacement in Real World Clinical Practice. Poster Presented at: ISPOR 22nd Annual International Meeting; May 20-24, 2017; Boston, MA.
4 Sadik, K, Flener J, Gargiulo J, Graves M, Nunley, R Post, Z, Wurzelbacher, Sutton, N, Hogan, Hollman, S, Ferko, N.  A U.S. Hospital Budget Impact Analysis of a Skin Closure System Compared with Standard of Care in Hip and Knee Arthroplasty. Poster Presented at: ISPOR 22nd Annual International Meeting; May 20-24, 2017Boston, MA.


SOURCE Ethicon

Related Links


b-ONE Ortho Receives U.S. FDA 510(k) Clearance for Total Hip System

September 21, 2018

CEDAR KNOLLS, N.J.–(BUSINESS WIRE)–b-ONE Ortho Corp., an emerging orthopedic technology company dedicated to the development of innovative healthcare solutions, today announced it has received 510(k) clearance for its first device, the b-ONETM Total Hip System, from the U.S. Food and Drug Administration (FDA).

The b-ONETM Total Hip System is a cementless total hip system with advanced coating technology and intuitive instrumentation, designed to optimize patient fit in the modern patient demographic. The system comprises the JuvenoTMFemoral Hip, a bone-conserving femoral prosthesis, and the b-ONE Primary Acetabular System, which are compatible with b-ONETM 12/14 Taper Femoral Heads.

“This milestone for the company will officially introduce b-ONE’s product line to the U.S. market,” said Dr. Mark Kester, the Chief Scientific Officer. “With our first U.S. surgery quickly approaching, we are eager to provide surgeons with a versatile system designed to accommodate the majority of today’s expanding patient demographic. In addition, with the support of Dr. Richard Rothman, a prolific designer and developer in the orthopedic industry, our strong R&D team will continue the development and expansion of our product portfolio with a focus on quality, affordability and speed to market.”

The b-ONETM Total Hip System will have a limited launch in the first half of 2019, followed by a full commercial release in the second half of 2019.

This news follows b-ONE Ortho Corp.’s recent US$20 million Series A financing led by Eight Roads Ventures and F-Prime Capital Partners. Proceeds are being used to fund the growth of b-ONE Ortho Corp.’s product portfolio and expansion into international markets.

About b-ONE Ortho Corp.

Based in Cedar Knolls, New Jersey, b-ONE Ortho Corp. is an emerging orthopedic technology company dedicated to the development of innovative orthopedic healthcare solutions that restore patient mobility and improve surgical outcomes. Every day we are committed to becoming the most credible choice for orthopedic products worldwide.

About Eight Roads

Eight Roads Ventures is a global venture capital firm that backs entrepreneurs with aspirations for greatness. As the proprietary investment arm of Fidelity International Limited, Eight Roads is committed to building bold and meaningful businesses and together with its associated funds has invested almost US$6bn globally into growing companies in the past 10 years.

Eight Roads Ventures has led successful investments in China and across the world, including Wuxi PharmaTech, Hile, Innovent, Adagene, Hua Medicine, DeltaHealth, Denali, doctorlink, Laurus Labs, Alibaba, China PnR, AsiaInfo, iSoftStone, Wisers, GShopper, Rulai and PingPong. It launched a dedicated US$250m China Healthcare Fund in September 2017.

About F-Prime Capital

F-Prime Capital Partners is a global venture capital firm investing in life sciences, healthcare, and technology. Since 1969, F-Prime has worked closely with entrepreneurs and academics to create innovative solutions to some of the world’s most significant challenges in healthcare and technology.

Caution Concerning Forward-looking Statements

This press release may contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995, regarding the Corporation’s expectations for future events. Such statements are based on currently available information and current expectations. If these assumptions prove incorrect or inaccurate, or known or unknown risks occur, actual results could differ materially from the expectations and projections of b-ONETM Ortho Corp. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Corporation disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.


For press enquiries, please contact:
b-ONE Ortho Corp.
Corinne Zappacosta
+1 (917) 733-8088
Related Links

Amplitude Surgical: 1st Arthroplasty Performed With an ANATOMIC® Total Knee Prosthesis in the United States

September 10, 2018

PARIS–(BUSINESS WIRE)–Regulatory News:

Amplitude Surgical (Paris:AMPLI) (ISIN: FR0012789667, Ticker: AMPLI, PEA-PME eligible), a leading French player on the global surgical technology market for lower-limb orthopedics, announces the first arthroplasty performed with an ANATOMIC® knee prosthesis in the United States, the world’s largest market, at a hospital in Champaign, Illinois.

The operation was performed by Dr. Sartawi, orthopedic surgeon, Director of Orthopedics at the Christie Clinic, Director of the OSF Heart of Mary Joint Care Center of Excellence and a Professor at the University of Illinois School of Medicine. At the same time, two total knee replacements using the ANATOMIC® system have been carried out by a surgeon in Florida, with very satisfactory results for both patients.

Olivier Jallabert, Chairman and CEO of Amplitude Surgical, says: “The implantation of a first ANATOMIC® knee prosthesis in the United States, the world’s largest market for lower-limb prosthetic reconstruction, represents a major milestone for Amplitude and the first step in our development on this market. The operation was a success, with the patient doing very well and able to get around without a walking stick just a week after her surgery, and I would like to thank Dr. Sartawi for his trust. Our Anatomic® knee system is proving to be a real success, with more than 50,000 prostheses already fitted worldwide, and we are proud to be able to make our innovative and reliable products and technologies available to American practitioners and patients to their great satisfaction”.

Next financial press release: 2017-18 annual results, on Wednesday October 17, 2018, after market.

About Amplitude Surgical
Founded in 1997 in Valence, France, Amplitude Surgical is a leading French player on the global surgical technology market for lower-limb orthopedics. Amplitude Surgical develops and markets high-end products for orthopedic surgery covering the main disorders affecting the hip, knee and extremities, and notably foot and ankle surgery. Amplitude Surgical develops, in close collaboration with surgeons, numerous high value-added innovations in order to best meet the needs of patients, surgeons and healthcare facilities. A leading player in France, Amplitude Surgical is developing abroad through its subsidiaries and a network of exclusive distributors and agents distributing its products in more than 30 countries. Amplitude Surgical operates on the lower-limb market through the intermediary of its Novastep subsidiaries in France and the United States. At June 30, 2018, Amplitude Surgical had a workforce of nearly 400 employees and recorded sales of over 100 million euros.


Amplitude Surgical
Philippe Garcia
+33 (0)4 75 41 87 41
Investor Relations
Marc Willaume
+33 (0)1 44 71 00 13
Media Relations
Nicolas Merigeau
+33 (0)1 44 71 98 55

Orthopedic Implants Market: Sales in Knee Reconstruction Pre-eminent, Hip Reconstruction to Gain Steady Momentum, slates Fact.MR

Rockville, MD, Aug. 08, 2018 (GLOBE NEWSWIRE) — The orthopedic implants market continues to be a promising avenue in the global medical technology space. Emergence of advanced technologies coupled with rise in orthopedic disorders are major growth determinants for the orthopedic implants market. A recent report by Fact.MR envisions the orthopedic implants market to record an august 6.5% CAGR over the forecast period 2018 to 2027. Although surgeries of orthopedic implants incorporating robotics offer reproducible precision and are less invasive, expensiveness of the technology coupled with the requirement for robust, evidence-based studies continues to impede its adoption in orthopedic surgeries.

The report opines that knee reconstruction will continue to hold major revenue shares of the orthopedic implants market, trailed by hip reconstruction. Governments across the globe are taking efforts to reduce prices of orthopedic implants used in knee reconstruction surgeries. For example, the National Pharmaceutical Pricing Authority (NPPA) has announced price caps on the orthopedic implants employed in knee reconstruction surgeries, bringing the basic models’ price down by 65%.

Request For Report Sample – https://www.factmr.com/connectus/sample?flag=S&rep_id=990

Additionally, the NPPA has also passed off most of the margins in trade, thereby alleviating concerns regarding impact of the orthopedic implants’ reduced prices on research & innovation. Such efforts from the government will further underpin growth of the orthopedic implants market in the near future. Orthopedic implant sales for knee reconstruction are envisaged to increase at 6.3% CAGR through 2027, according to Fact.MR study. In case of hip reconstruction surgeries, dislocation of orthopedic implants has prevailed as a prominent concern among patients and healthcare professionals alike.

A recent study carried out by a well-known research director, Geoffrey Westrich, unveiled that patients receiving newer implants, referred to “dual mobility,” has zero dislocation tendency in hip reconstruction and replacement. Researchers have found out dual-mobility orthopedic implants to have no dislocations post three-year follow-up of patients.

Results of the study are considered encouraging to meet active, high demand for orthopedic implants among patients, and are likely to lessen concerns apropos of dislocation. Such novel revelations and discoveries will continue to propel demand for orthopedic implants associated with hip reconstruction. Revenues from sales of orthopedic implants for hip reconstructed exceeded US$ 16,800 Mn in 2017.

North America’s preeminent in the orthopedic implants market will continue to prevail, states Fact.MR study. According to American Joint Replacement Registry (AJRR), over 7 million America have been associated with knee and hip reconstruction surgeries collectively. Over half revenue share of the market will be accounted by orthopedic implants sales in North America by 2027-end.

To know the Latest Trends in Orthopedic Implants Market, Visit – https://www.factmr.com/report/990/orthopedic-implants-market

The U.S. Food and Drug Administration (FDA) has approved a slew of robotic surgery systems for orthopedic implants, with the da Vinci Surgical System being the first one. More companies have been investing in the technology for providing a better navigation during the procedure, and obtain 3D scans to aid designing of customized joints.

Acquisitions and mergers continue to be key strategic expansion methods adopted by companies operating in the orthopedic implants market. Acquisition of Mako Surgical Corp. by Stryker – for total hip and knee construction robotic products for orthopedic implants, and Blue Belt Holdings by Smith & Nephew for robot-assisted orthopedic implant surgery product for partial knee replacements are prime instances of such strategic expansions.

Continues advancements in orthopedics have resulted in the development of new, novel implants, with several of them being employed in clinical practices with none or little evidence on their effectiveness and safety. Appropriate staging of new orthopedic implants implementation is therefore gaining emphasis in the market, to eliminate relevant adverse effects on patients. Methodologies for evaluation of new orthopedic implants are now being used as a base for contemplating their success and resolving observed drawbacks.

To Buy Orthopedic Implants Market Report, Check the page- https://www.factmr.com/checkout/990/S

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Contact Us

Rohit Bhisey


11140 Rockville Pike

Suite 400

Rockville, MD 20852

United States

Email: sales@factmr.com

Web: https://www.factmr.com/

Top Joint Replacement Surgeon To Lead NYU Langone’s Adult Reconstructive Surgery Division

NEW YORKSept. 10, 2018 /PRNewswire/ — William Macaulay, MD, an internationally renowned expert in hip and knee treatments and surgery, has been appointed Chief of the Division of Adult Reconstructive Surgery in the Department of Orthopedic Surgery at NYU Langone Health. The new appointment is effective August 23, 2018.

Dr. Macaulay first joined NYU Langone in January 2017 as its medical director for International Patient Services. In that role he oversaw an expansion of the health system’s program matching international patients with top physicians in a wide variety of medical and surgical disciplines. He will maintain this position as he assumes his new role.

Macaulay also serves as professor of orthopedic surgery in the Division of Adult Reconstructive Surgery, performing his surgical procedures at NYU Langone Orthopedic Hospital in Manhattan. In addition, he consults with patients at several of NYU Langone’s state-of-the-art outpatient facilities, including the Preston Robert Tisch Center for Men’s Health in Manhattan and NYU Langone Orthopedics—Westchester.

“We are thrilled to have Dr. Macaulay’s vast orthopedic expertise and renowned leadership spearheading NYU Langone’s adult reconstructive surgery division,” says Joseph D. Zuckerman, MD, the Walter A. L. Thompson Professor of Orthopedic Surgery and chair of the Department of Orthopedic Surgery. “Dr. Macaulay enjoys international acclaim, and will apply his experience to continue to elevate our division, which is recognized for its extensive clinical, educational and academic activities.”

About Dr. Macaulay: A Leader in Hip and Knee Care

Dr. Macaulay specializes in orthopedic procedures including primary and revision total knee and total hip replacement, partial knee replacement, hip resurfacing, hip fracture repair and knee arthroscopy. For the most complex cases, he utilizes new technologies, including robotics and computer-assisted navigation, to ensure optimal outcomes.

Prior to joining NYU Langone, Dr. Macaulay served as chief of the Division of Hip and Knee Surgery and director of the Center for Hip and Knee Replacement at NewYork-Presbyterian (NYP) at Columbia. He also served as the director of Orthopedic Surgery at NYP/Lawrence Hospital in Westchester County, and had been a member of the faculty at Columbia University Medical Center for 17 years, acting as Advisory Dean at The College of Physicians and Surgeons for 7 years. He was also the founder and director of their hip and knee replacement fellowship program. Dr. Macaulay earned his medical degree from Columbia University College of Physicians and Surgeons, and completed his surgery internship and orthopedic surgery residency at University of Pittsburgh Medical Center. He also completed a postdoctoral arthroplasty fellowship at the Hospital for Special Surgery in New York.

An accomplished researcher and clinician, Dr. Macaulay has received more than a dozen awards and honors for his work in hip and knee orthopedic care. He was named one of the “25 Best U.S. Knee Surgeons” by Becker’s ASC Review. He is also a member of several prestigious medical societies, including The Hip Society, The Knee Society, and the American Association of Hip and Knee Surgeons, the latter of which presented him with the Lawrence D. Dorr Surgical Techniques and Technologies Award in 2007. For the last two decades, Dr. Macaulay’s research has focused on advances in hip and knee reconstructive surgery, such as surgical recovery enhancement and outcomes of hip and knee replacement surgery, including partial knee replacement and hip resurfacing. He has served as a site investigator, principal investigator, and steering committee member of several prominent randomized clinical trials.

“It’s a true honor to be selected to oversee one of the largest and most renowned adult reconstructive surgery divisions in the United States, whose faculty is lauded for pushing the envelope in cutting-edge treatments and new research to provide top orthopedic care,” says Macaulay.

Why Choose NYU Langone for Joint Replacements

The Adult Reconstructive Surgery Division at NYU Langone is one of the largest in the country, with 36 surgeons who performed more than 4,500 procedures last year. Our total joint replacement surgeons are experienced in minimally invasive joint replacement techniques and work with the latest technology and equipment in specialized orthopedic operating rooms. They use their expertise in planning, as well as during, all surgical procedure to address their patient’s joint problems and ensure the best possible outcomes.

NYU Langone ranks No. 8 in the nation in Orthopedics, according to U.S. News & World Report‘s “Best Hospitals 2018-2019 Honor Roll.” It also ranks No. 2 in New York State and number two in the New York metro area. Equally noteworthy, NYU Langone is the only hospital in New York to receive top 10 rankings for all three musculoskeletal specialty disciplines: orthopedics, rheumatology, and rehabilitation.

Patients who choose to travel from outside of the United States can find expert assistance at NYU Langone, where care coordinators match patients with the appropriate doctors and treatment options. The team also helps arrange travel and local accommodations for accompanying family members, and ensures patients have medical interpreters during all phases of care, including via telephone, video, or face-to-face consultations.

International patients seeking care can contact NYU Langone’s International Patient Services Program at (212) 263-3588, or by email at internationalservices@nyulangone.org. Please include your name, country of origin, preferred contact method, and preferred language. Documents can also be faxed to 646-501-5296.

Media Inquiries:

Ryan Jaslow

Phone: 212-404-3511


SOURCE NYU Langone Health

Photo: (PRNewsfoto/NYU Langone Health)

LimaCorporate Announces Milestone-based Acquisition of TechMah Medical LLC to Expand Digital Footprint in Orthopaedics

SAN DANIELE DEL FRIULI, ItalySeptember 6, 2018 /PRNewswire/ —

LimaCorporate, a pioneer and leader in 3D printing of Orthopaedic implants, announces the milestone-based acquisition of TechMah Medical LLC (“TechMah Medical”), a medical device software company located in Knoxville, Tennessee, to complement its hardware portfolio with digital applications.

TechMah Medical was founded in 2014 and focuses on digital technologies dedicated to orthopaedic surgery that impacts the quality of care and fits into today’s cost constraints.  Dr. Mohamed Mahfouz, Professor of Biomedical Engineering at the University of Tennessee, is the founder of TechMah Medical.  Dr. Mahfouz has over 20 years’ experience within Orthopaedics and holds over 300 publications on implant design, imaging, kinematics, sensors, anthropology and forensics. Dr. Mahfouz will continue to be involved with TechMah Medical and will become a long-term partner to LimaCorporate.

The team at TechMah Medical consists of world-class researchers and engineers in bio-wireless electronics, biomechanics, imaging, as well as software and will focus on the release of software and smart instruments which will be used in combination with LimaCorporate implants.

This investment in software know-how, together with the internal 3D printing expertise, brings LimaCorporate to the forefront of digital transformation of the Orthopaedics industry through highly-innovative digital solutions that will change the approach to surgery and standard instrumentation.

Under the terms of the agreement, LimaCorporate will provide funding to TechMah Medical and complete the acquisition as key product development goals are achieved, becoming the sole shareholder of TechMah Medical over time, while Dr. Mahfouz and his team will remain involved with the business.  Financial terms have not been disclosed.

“LimaCorporate is the most innovative and agile company in Orthopaedics today and the ideal partner for us to develop our technology and advance the digitization of the industry,” said Dr. Mahfouz from TechMah Medical.

Luigi Ferrari, CEO of LimaCorporate, commented, “We are excited about this transaction and the partnership with Dr. Mahfouz. Combined with our proven implant technology and 3D printing capabilities, this acquisition will allow LimaCorporate to develop a strong foothold in all digital applications surrounding Total Joint Replacement by offering surgeons a new intra-operative experience and by providing their patients flexible personalized care.”

About LimaCorporate

LimaCorporate is a global medical device company providing reconstructive Orthopaedic solutions to surgeons who face the challenges of improving the quality of life of their patients. Based in Italy, LimaCorporate is committed to the development of innovative products and procedures to enable surgeons to select ideal solution for every individual patient. LimaCorporate’s product range includes large joint revision and primary implants and complete extremities solutions including fixation.

About TechMah Medical 

TechMah Medical LLC is a technology company focused on delivering orthopedic solutions. We build innovative applications designed to improve patient and clinician experience throughout the joint replacement process. Based in Knoxville, Tennessee, our team of scientists and engineers are driven to improve quality and efficiency through customization.

For additional information on the Company, please visit: limacorporate.com

Limacorporate S.p.A.

Via Nazionale, 52

33038 Villanova di San Daniele

Udine – Italy

T: +39-0432-945511

E: info@limacorporate.com

SOURCE Limacorporate S.p.A

Promising ACL surgery outcomes for aging athletes

ROSEMONT, Ill.Aug. 21, 2018 /PRNewswire/ — One of the most common knee injuries is an anterior cruciate ligament (ACL) sprain or tear, and doctors are seeing a greater number of older athletes end up in their offices with the injury. An estimated 200,000 ACL-related injuries occur annually in the United States.

Some patients choose to undergo surgical reconstruction of the ACL while others opt for non-surgical intervention. A new review article published in the August 15th issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS) discusses surgical and non-surgical treatment options for patients over the age 40 with ACL injuries and proposes shared decision-making about care between patients and doctors.

“The benefits of staying active throughout your life greatly outweigh the risks,” emphasized lead study author and orthopaedic surgeon Matthew Salzler, MD. “ACL tears are an unfortunate but treatable injury that can occur, especially in sports that require sudden twisting and pivoting movements.”

Aging ACLs have a reduced potential to heal and a lower capacity to bear significant strain, as demonstrated in one study highlighted in the review article that compared rats injected with younger and older human ACL-derived cells. Older ACLs may also show greater degeneration.

The review article authors highlight that deciding between surgical and non-surgical treatment options depends on a patient’s activity level and should be a part of a doctor’s initial evaluation when treating patients for an ACL injury. The patient’s history of knee injuries and functional needs should be considered.

According to the article patients of all ages benefit from the rest, ice, compression and elevation (RICE) approach; therefore, this should be the initial management for ACL injuries. This helps reduce pain and swelling, and protects the knee from additional injury. In addition, early physical therapy may help return range of motion and knee stability.

The review article also highlights that the “rule of thirds” has been used for over 25 years to describe different types of patients. They may be classified as:

  • Copers: Able to resume all of their previous activity without any issues for at least one year after the injury.
  • Adapters: Modify or reduce activity after their injury.
  • Non-copers: Require ACL reconstructive surgery because they can’t get through everyday tasks.

The authors explained that though this pattern is not evidence-based, the concepts are relevant when treating patients over 40 as they’re more likely than younger patients to modify their activity over opting for surgical reconstruction.

The article states that the ideal candidates for reconstructive surgery are generally patients who haven’t shown enough improvement with physical therapy alone, want to participate in sports that require sudden pivoting or cutting – like basketball or skiing – and don’t have extensive degenerative changes.

In two systematic reviews of older patients who underwent ACL reconstruction, improvements and positive outcomes were found in knee stability and patient satisfaction. The Swedish National Anterior Cruciate Ligament Register also reported that while older patients had worse knee injury and osteoarthritis scores before surgery than younger patients, their scores after surgery were markedly better, and they showed the greatest improvement one, two, and five years after surgery.

“The outcomes of ACL reconstruction surgeries in patients over 40 are as good as – if not better than – those in younger patients,” says Dr. Salzler.

For patients leaning towards avoiding surgery, the study authors point out that there is conflicting data on the outcomes of nonsurgical treatment in those older than 40. One study of patients with ACL injuries aged 40 to 59 years that did not have surgery had worse outcomes than those that underwent reconstruction. However, in a separate study of Alpine skiers, those treated without surgery fared better than surgical patients.

“As with younger patients, an insufficient or torn ACL is likely to lead to an increased risk of knee instability, meniscal tears, and arthritis,” Dr. Salzler explains. “Whether a patient undergoes surgery or attempts non-operative management of an ACL tear requires a discussion with their orthopaedist.”

The full study is available at: http://bit.ly/2mq18yI

More information about the AAOS and JAAOS 

Follow the AAOS on FacebookTwitter and Instagram 

Follow the conversation about JAAOS on Twitter


From Department of Orthopaedics, Tufts Medical Center, Boston, MA (Dr. Salzler), the Department of Orthopedics, University of Colorado at Denver, Anschutz Medical Campus, Aurora, CO (Dr. Chang), and Boston Sports and Shoulder Center, New England Baptist HospitalWaltham, MA (Dr. Richmond). Dr. Salzler or an immediate family member is a board member or committee member of the American Orthopaedic Society for Sports Medicine. Dr. Richmond or an immediate family member serves as a paid consultant to Histogenics, Mitek, and Visgo Therapeutics; has received royalties and financial or material support from Springer and Wolters Kluwer Health–Lippincott Williams & Wilkins; and is a board member or committee member of the Arthroscopy Association of North America and Eastern Orthopaedic Education Foundation. Neither Dr. Chang nor any immediate family member has received anything of value from or has stock or stock options held in a commercial company or institution related directly or indirectly to the subject of this article. J Am Acad Orthop Surg 2018; 0:1-9 DOI: 10.5435/JAAOS-D-16-00730 Copyright 2018 by the American Academy of Orthopaedic Surgeons.

SOURCE American Academy of Orthopaedic Surgeons

Related Links